- PR Newswire•6 days agoCytoSorbents Congratulates Kathleen Bloch as NJBIZ Public Company Chief Financial Officer of the Year
MONMOUTH JUNCTION, N.J., Oct. 17, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® extracorporeal cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, is pleased to congratulate Kathleen Bloch, Chief Financial Officer (CFO) of CytoSorbents, as the winner of the NJBIZ Public Company CFO of the Year Award, announced Friday, October 14th at the annual awards ceremony. Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "We are very proud of Kathy and this award that reflects her many accomplishments not just at CytoSorbents, but throughout her long and successful career. Kathy's contributions to our company run far and wide, and include for example, helping to establish and execute upon our global strategy, spearheading the up-listing to NASDAQ and ensuring ongoing SEC and Sarbanes Oxley compliance, and managing the financing and financial needs of this rapidly growing, vertically integrated manufacturer of CytoSorb® that through the effort of more than 70 employees over 2 continents, is saving lives and generating strong sales growth across a 40-country network of distributors, strategic partners, and our own direct sales team.
- PR Newswire•9 days ago
MONMOUTH JUNCTION, N.J., Oct. 14, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® extracorporeal cytokine adsorber ...
- PR Newswire•12 days ago
MONMOUTH JUNCTION, N.J., Oct. 11, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has signed an exclusive distribution agreement with Foxx Medical Chile SpA (Foxx Medical) to distribute CytoSorb for all critical care, cardiac surgery, and other hospital applications in Chile. This multi-year agreement is subject to annual minimum purchases of CytoSorb to maintain exclusivity. Mr. Patrick Ward, General Manager and Chairman of Foxx Medical stated, "We are excited to commence our partnership with CytoSorbents.
Cytosorbents Corporation (CTSO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Ask||6.00 x 100|
|Day's Range||5.40 - 5.65|
|52wk Range||3.11 - 8.10|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-14.64|
|Avg Vol (3m)||88,557|
|Dividend & Yield||N/A (N/A)|